Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the cognitive changes after administration of
tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in
patients with mild to moderate Alzheimer's disease.
After the 26 week core treatment period, the patients may continue in the study under blinded
conditions for an optional extension period up to a maximum of 39 additional weeks (total
study duration up to 65 weeks), until the last patient in the study has completed the 26 week
of treatment.